The return of biotech’s “bump factor” amid an economic downturn

Off Biotech, biotechnology, Business, CRISPR, drug development, drug pricing, FDA, finance, genetics, Health, health care, Human Health, Life Sciences, Medicine, Pharmaceuticals, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with a deep dive on a historic moment for genome editing, mixology tips from a biotech lifer, and a look at why scientists are interested in muscle-building drugs.

Read the rest…

Read Original Article: The return of biotech’s “bump factor” amid an economic downturn »

About The Author